科伦药业(002422.SZ)子公司ITGB6 ADC SKB105新药临床试验申请获国家药监局批准

Core Viewpoint - The company has received approval for its clinical trial application for the targeted integrin β6 antibody-drug conjugate SKB105 (also known as CR-003) for the treatment of advanced solid tumors from the National Medical Products Administration (NMPA) in China [1] Group 1 - The company's subsidiary, Sichuan Kelun Biopharma Co., Ltd. (Kelun Biopharma), is responsible for the development of SKB105 [1] - A strategic collaboration has been established between Kelun Biopharma and Crescent Biopharma, Inc. regarding SKB105/CR-003 and SKB118 (a bispecific antibody targeting PD-1 and VEGF, also known as CR-001) [1] - Under the collaboration, Kelun Biopharma grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105/CR-003 outside of Greater China, while Crescent grants Kelun Biopharma exclusive rights for SKB118/CR-001 within Greater China [1] Group 2 - Kelun Biopharma plans to submit an IND application for SKB118/CR-001 to the NMPA in the near future [1]